(Reuters) – Moderna Inc on Tuesday stated its experimental COVID-19 vaccine induced a strong immune response and guarded towards an infection in a examine on monkeys.
The vaccine, MRNA-1273, given to non-human primates protected towards an infection within the lungs and nostril, and prevented pulmonary illness in all animals, the corporate stated in a information launch. Outcomes of the examine in rhesus macaque monkeys have been printed within the New England Journal of Medication.
It gave the impression to be an enchancment over outcomes of AstraZeneca’s COVID-19 vaccine in an identical examine.
Whereas outcomes of the animal examine might increase confidence within the vaccine, Moderna has already begun testing it in people.
On Monday, the corporate started a late-stage examine that intends to check its messenger RNA vaccine towards a placebo in 30,000 wholesome volunteers. Constructive leads to that trial might clear the best way for regulatory approval and widespread use as early as the top of this yr.
Efficient vaccines are seen as crucial to ending a pandemic that has taking the lives of greater than 655,000 folks globally.
Within the examine involving 24 monkeys, Moderna examined doses of 10 micrograms or 100 micrograms of the vaccine towards no remedy.
Each doses proved efficient at defending towards viral replication within the lungs and lung irritation, with the bigger dose additionally defending towards viral replication within the nostril of the animals.
A rival vaccine being developed by AstraZeneca and Oxford College – among the many most superior in human trials – in an identical animal examine additionally appeared to stop harm to the lungs and maintain the virus from making copies of itself there. However the virus nonetheless actively replicated within the nostril in that examine.
Moderna, which has by no means introduced a vaccine to market, has acquired practically $1 billion from the U.S. authorities for its efforts. The USA helps bankroll a number of vaccine candidates underneath its Operation Warp Pace program.
Moderna shares rose about 2%.
Reuters Well being Info © 2020 Reuters Ltd.
Republication or redistribution of Reuters content material, together with by framing or comparable means, is expressly prohibited with out the prior written consent of Reuters. Reuters shall not be responsible for any errors or delays within the content material, or for any actions taken in reliance thereon. Reuters and the Reuters sphere emblem are registered logos and logos of the Reuters group of firms around the globe.
Cite this: Moderna Vaccine Protects Towards COVID-19 in Monkey Research – Medscape – Jul 30, 2020.